Abstract Number: PB0060
Meeting: ISTH 2020 Congress
Theme: Arterial Thromboembolism » Cardiovascular Risk Factors
Background: Aspirin is indispensable in secondary prevention of ischemic events. Recently, it was reported that clinical aspirin effects are hampered in patients above 70 kg body weight. It is well known that a plethora of reasons beside obesity is associated with increased platelet reactivity and insufficient aspirin effects (HTPR).
Aims: However, data regarding an association between pharmacodynamic response to aspirin and body weight are missing.
Methods: In this pilot study, we included 59 patients from University Hospital Duesseldorf. Impedance aggregometry was used to assess pharmacodynamic response to aspirin.
Results: AA-induced platelet reactivity was significantly higher in patients above 70kg (< 70kg: 28.27 ± 26.33 vs. >70kg: 45.93 ± 27.1, p=0.035) and correlated well with the bodyweight of patients in this study (r=0.33, R²=0.09, p=0.016). According to this, insufficient pharmacodynamic response (HTPR) to aspirin was significantly more frequent in patients over 70kg (< 70kg: 25% vs. >70kg: 43%, p=0.035).
Conclusions: Insufficient pharmacodynamic response to aspirin is associated with body weight. This finding may play a role in the impaired clinical efficacy of aspirin in patients > 70 kg. An optimal aspirin regime in these patients needs to be evaluated in large scale trials.
To cite this abstract in AMA style:
Mourikis P, Zako S, Dannenberg L, Helten C, Naguib D, Hohlfeld T, Petzold T, Levkau B, Zeus T, Kelm M, Polzin A. Aspirin Antiplatelet Effects Are Associated with Body Weight [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/aspirin-antiplatelet-effects-are-associated-with-body-weight/. Accessed September 29, 2023.« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/aspirin-antiplatelet-effects-are-associated-with-body-weight/